Biotech
-
400Nemus Bioscience Inc (OTCMKTS:NMUS) Turns Bullish On Emerald Health $20 Million Credit Line Boost
Nemus Bioscience Inc (OTCMKTS:NMUS) continues to elicit strong investor interest after reaching an agreement for a $20 million credit facility. With the...
-
433GT Biopharma Inc. (OTCMKTS:GTBP): FDA Clinical Trials Clearance Reinvigorates Long-Term Prospects
A third quarter financial report attesting to a solid foundation for long-term growth might as well be the catalyst, poised to trigger...
-
5791Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Bulls Regain Control
Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) powered high on equity research firm ValueEngine initiating coverage of the stock with a ‘buy’ rating....
-
325Imagin Medical Inc (CNSX:IME) Trying To Bottom Out
Price action activity points to a possible turnaround in Imagin Medical Inc (CNSX:IME) prospects especially on the formation of a double bottom....
-
7861Reliq Health Technologies Inc (CVE:RHT) A Long-Term Play As Demand For Telemedicine Solutions Soar
Reliq Health Technologies Inc (CVE:RHT) is due for a major bounce back after hitting rock bottom. The stock has already bottomed out...
-
2.0K3Why FSD Pharma Inc (CNSX:HUGE) Is A Buy
There are but only a few companies globally which can brag about having doubled their market capitalization over a two-month period. Even...
-
518Vodis Pharmaceuticals Inc (CNSX:VP): Weak Underlying Fundamentals Spell Trouble Despite Rally
Trading activity around Vodis Pharmaceuticals Inc. (CNSX:VP) stock has picked up the pace, depicted by high turnover in traded shares. However, a 100%...
-
898Scythian Biosciences Corp (CNSX:SCYB) Focused On Venturing Into the U.S. Market
The year has been a roller coaster for Scythian Biosciences Corp (CNSX:SCYB). Generally, the company has experienced one of its longest bear...
-
524Earth Science Tech Inc (OTCMKTS:ETST) Gets A $3.60 Price Target
Earth Science Tech Inc (OTCMKTS:ETST) is showing signs of trading higher following a string of positive developments that have renewed investor interest...
